Stay updated on Pembrolizumab + Ipilimumab vs. Placebo in NSCLC Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab + Ipilimumab vs. Placebo in NSCLC Clinical Trial page.

Latest updates to the Pembrolizumab + Ipilimumab vs. Placebo in NSCLC Clinical Trial page
- Check3 days agoChange DetectedVersion label updated from v3.0.1 to v3.0.2; the Back to Top link was removed.SummaryDifference0.1%
- Check10 days agoChange DetectedThe web page has been updated from version 3.0.0 to version 3.0.1, and a 'Back to Top' feature has been added.SummaryDifference0.1%
- Check18 days agoChange DetectedThe webpage has undergone significant updates, including the addition of numerous specific locations across various countries and the removal of some previously listed locations. Additionally, there are new entries related to drug safety and pharmaceutical preparations.SummaryDifference16%
- Check25 days agoNo Change Detected
- Check32 days agoChange DetectedThe web page has been updated from version 2.16.11 to version 2.16.12.SummaryDifference0.0%
- Check39 days agoChange DetectedThe web page has been updated from version 2.16.10 to version 2.16.11.SummaryDifference0.0%
- Check46 days agoChange DetectedThe web page has been updated to version 2.16.10, and a previous service alert regarding planned maintenance has been removed.SummaryDifference0.5%
Stay in the know with updates to Pembrolizumab + Ipilimumab vs. Placebo in NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab + Ipilimumab vs. Placebo in NSCLC Clinical Trial page.